Pharma BD Deal Intelligence
A small ($275M-$450M) tuck-in that quietly became one of Roche Diagnostics' most durable franchises — cobas Liat is still a named, market-moving revenue line 12 years later.
Full analysis, sources & comparables →Roche Diagnostics COO Roland Diggelmann said the acquisition strengthens Roche's molecular offerings 'with cutting-edge technology and products that serve the…
DeciBio framed Roche's purchase as filling 'a glaring hole' in the company's MDx portfolio and matching bioMerieux's January 2014 BioFire deal, signaling a…
KEI documents that the Liat PCR device, originally developed with US government funding, was acquired by Roche in 2014 for up to $450M and went on to underpin…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche acquired Massachusetts-based IQuum for $275M upfront plus up to $175M in product-related milestones, securing the Liat lab-in-a-tube system for point-of-care molecular diagnostics. The deal extended Roche's leadership in molecular diagnostics into the decentralized testing setting.
A small ($275M-$450M) tuck-in that quietly became one of Roche Diagnostics' most durable franchises — cobas Liat is still a named, market-moving revenue line 12 years later.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / IQuum, Inc. (this deal) | 2014 | $450M | 79 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Infectious Disease deals